Compare Mesoblast Limited (MESO) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vanguard High Dividend Yield ETF — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while Vanguard High Dividend Yield ETF trades at $166.57. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | VYM | |
|---|---|---|
Market Cap | $2.16B | — |
Sector | Technology | — |
52-Week High | $20.96 | $166.14 |
52-Week Low | $12.88 | $136.63 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
VYM trades at $165.63, up 0.52% today, near its 52-week high with strong bullish momentum from moving averages. The ETF's technicals show overbought RSI signals but positive ADX trends, while recent news highlights its role in retirement income strategies. A dividend of $0.98 is scheduled for June 2026, reinforcing its income focus amid institutional adjustments.
Outlook remains positive for income-seeking investors due to VYM's dividend reliability and sector diversification, though overbought conditions and underperformance versus the S&P 500 pose risks. Key opportunities include sustainable yield; risks involve market volatility and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
